Loading organizations...
Mizuho Securities engages in principal investment activities, strategically deploying its own capital into private equity and venture capital opportunities. This involves providing direct financial backing to companies across various growth stages, with an emphasis on creating long-term value. The firm’s approach integrates rigorous financial analysis with a deep understanding of market dynamics, aiming to foster the development and expansion of its portfolio companies.
The principal investment function within Mizuho Securities gained a dedicated structure with the establishment of Mizuho Securities Principal Investment in 2005. This initiative represented a strategic commitment by Mizuho Securities to participate actively in the private markets, leveraging its considerable financial expertise and extensive network to identify and cultivate promising investment opportunities within its broader financial services framework.
The ventures benefiting from Mizuho's principal investment efforts span various industries, receiving not only essential growth capital but also strategic guidance. The overarching vision is to enhance shareholder value for Mizuho Financial Group by meticulously identifying and nurturing businesses with significant potential. This strategy aims to contribute to economic development and broaden the group's influential footprint across diverse investment sectors.
Mizuho Securities Principal Investment has 3 tracked investments across 3 companies. The latest tracked deal is $8.5M Series A in Suono Bio in July 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 13, 2021 | Suono Bio | $8.5M Series A | Fred Shane, Mizuho Securities Principal Investment | — |
| Jun 16, 2020 | C4 Therapeutics, Inc. | $170.0M Debt / Series B | Todd Kaloudis, Adam Stone | 3E Bioventures Capital, Adage Capital Management, Axil Capital, Bain Capital Life Sciences, Commodore Capital, HBM Healthcare Investments, Janus Henderson Investors, Lightchain Capital, Logos Capital, Nextech, RA Capital Management, RTW Investments, Sphera Funds Management, T. Rowe Price Associates, Yonjin Capital |
| Jul 23, 2019 | Frequency Therapeutics | $62.0M Series C | Joseph Edelman | Axil Capital, Cobro Ventures, Deerfield Management, Polaris Founders Capital, RTW Investments |